Abstract
INTRODUCTION AND OBJECTIVES:
Erectile dysfunction (ED) affects over 70% of men with end-stage renal disease (ESRD), yet the cardiovascular safety of phosphodiesterase type 5 inhibitors (PDE5i) in this population remains poorly understood. Concerns persist due to altered...